Le Lézard
Classified in: Health, Business
Subjects: CON, LIC

HR Pharmaceuticals, Inc. receives exclusive commercialization rights to Poiesis Medical's Dual Balloon Catheter technology in North America


YORK, Pa., Dec. 28, 2023 /PRNewswire/ -- Today, HR Pharmaceuticals, Inc. (HRP) announced that they have entered into an Exclusive Commercial Agreement with Poiesis Medical LLC, under which HRP will license Poiesis's Dual Balloon Catheter (Duettetm). Under the terms of the agreement, HRP will have exclusive commercialization rights in North America. This product expands HRP's growing urological portfolio across the continuum of care, providing a novel design to help address adverse events associated with Foley catheterization, which is critically important for specific patient populations.

"The Dual Balloon Catheter has demonstrated significant benefits compared to traditional Foley catheters, leading to better patient outcomes. Specifically, we see a great opportunity for patients requiring indwelling catheterization greater than five days. This product will become an important part of our broader urology strategy over the next 12 months," states Colby Wiesman, President of HR Pharmaceuticals, Inc. 

"The Dual Balloon Catheter technology, a brainchild of my father, Dr. Bruce Wiita, a practicing urologist and decorated Vietnam veteran, was born out of a genuine desire to improve the quality of life for patients enduring prolonged catheterization and to alleviate the strains it places on the healthcare system," says Gregory Wiita, CEO and Founder at Poiesis Medical LLC. "We are excited about this new chapter with HR Pharmaceuticals and the potential of the technology to make a meaningful impact in patient care." 

HRP will begin processing North American orders for the Duette Dual Balloon Catheters starting January 2, 2024. Duette is available at most national distributors, including Cardinal Health, McKesson, Medline, and Owens & Minor. For further assistance or additional information, please contact HRP at [email protected] or 800.302.1110. 

About HR Pharmaceuticals, Inc. 
HR Pharmaceuticals, Inc. is a professionally managed, family-owned business located in York, PA, that develops, manufactures, and supplies products for a variety of markets. HR is an industry expert in healthcare consumables and offers a broad range of products, from medical lubricants and ultrasound gels to a comprehensive continence care offering and more. HR's mission - positively impacting people's lives- unifies the organization and drives an unwavering commitment to customers. For more information on HR Pharmaceutical, Inc., visit hrpharma.com.

About Poiesis Medical LLC 
Poiesis Medical LLC is a family-oriented business co-founded by Dr. Bruce Wiita and his son Gregory Wiita. The father-son team has been at the forefront of medical innovation for 25 years. The company's journey spans several successful ventures, marked by significant contributions to robotic radiotherapy in prostate cancer care and developing safety devices for laparoscopic lymphadenectomy surgery. With a history of successful partnerships and exits, including three acquisitions, the legacy of innovation continues with a focus on delivering advanced urinary products to provide better patient care.

Duette is a trademark of Poiesis Medical LLC. 

SOURCE HR Pharmaceuticals


These press releases may also interest you

at 19:32
Vistra announced today that its board of directors has declared a quarterly dividend of $0.2175 per share of Vistra's common stock, reflecting an estimated aggregate payment of $75 million this quarter. This represents an approximate 7% increase in...

at 19:25
Realeo, Inc., a leading provider of innovative real estate solutions, proudly announces the establishment of its newest subsidiary, Realeo Title Company, a California Corporation licensed as an underwritten title company in all 58 counties. Realeo...

at 19:23
Multiple achievements were made on Thursday at a conference focused on cooperation between China and Hungary under the Belt and Road Initiative (BRI) framework. Under the guidance of China's State Council Information Office, the conference was...

at 19:05
Gold Resource Corporation (the "Company") is pleased to announce its first quarter operational results from its Don David Gold Mine ("DDGM") near Oaxaca, Mexico, and a corporate update on its other activities. 2024 Q1 Highlights include:...

at 18:53
1Q24 Highlights Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of R$ 2.8 billion in the first quarter, up 38.0% over 4Q23. Adjusted Net Income of R$ 1.2 billion in 1Q24, 70.1% higher than 4Q23. Dividend distribution...

at 18:40
Forum Energy Technologies, Inc. today announced first quarter 2024 revenue of $202 million, a 9% sequential increase. Orders grew 28% sequentially to $204 million, with a book-to-bill ratio of 101%. The first quarter 2024 net loss was $10 million,...



News published on and distributed by: